Provalis PLC
17 June 2004

For Immediate Release 17th June 2004

Provalis Files G5 Diabetes Test with FDA and builds USA Sales Team

Provalis plc (LSE: PRO; NASDAQ: PVLS), the Medical Diagnostics and
Pharmaceuticals Group, is pleased to announce that, on schedule, it has filed
the USA regulatory submission with the FDA for its G5 diabetes glycated
haemoglobin test.

Regulatory clearances are being sought in the USA for 510K and prescription home
use marketing approvals, which additionally confers CLIA waiver. These allow
the Company to fully exploit the sales potential of G5 into all physicians'
offices and also to be available eventually to diabetics for use at home.

In further preparation for the launch of the product in the USA, Provalis has
now appointed its three vice-presidents of sales to cover the central, west
coast and east coast regions. They, together with Bert Valada the General
Manager of Provalis Diagnostics (USA), have collectively over 100 years of
diagnostics sales experience in the USA and are now building the network of
national sub-distributors ready for product launch in the autumn (fall) of this
year.

Phil Gould, Chief Executive Officer of Provalis said 'We are delighted with the
high quality of the clinical data we have generated with G5 and that we have now
filed on schedule the USA regulatory submission with the FDA. With an
experienced sales team now recruited in the USA, we look forward to a successful
product launch in the autumn of this year'.

END

Provalis' Internet Website ;
http://www.provalis.com


Comment - Provalis has a market cap of 17m. At one time, when called Cortecs, the company was a medium sized pharma. During the tech bubble it lost its way and eventually had to re-invent itself. It re-directed its efforts to the diagnostic side of the market, finally producing Glycosal, a physician's office blood-testing equipment for diabetics. Another rights' issue later and it has finally filed for G5 approval (allowing for a similar test for home use). It has decided to create its own market distribution network - very risky. It is against some much larger competitors such as Axis-Shield (Afinion) which are closer to marketing their own versions of G5 - even offering multi-platform testing - but in less than 90 days Pro will also be selling its G5 product. Diabetes is a huge market, as we all know from reading about obesity etc. Pro only has to catch a small slice of this market to increase its market cap many times over. A very risky punt but it could be rewarding if you get in at the bottom. 7.125p mid-price at the time of writing.

Provalis PLC
1 July 2004


For Immediate Release 1st July 2004


Provalis plc


Provalis signs Vaccine Option Agreement with Chiron Vaccines


Provalis plc (LSE: PRO; NASDAQ: PVLS), the Medical Diagnostics and
Pharmaceuticals Group, today announces that it has signed an option agreement
with Chiron Vaccines. Under the terms of the agreement:


Chiron Vaccines is granted an initial 12 month, exclusive
option (extendable by a further 12 months on payment of a fee) to evaluate
Provalis' protein based vaccine candidates to prevent Group B Streptococcus
infection;

Chiron Vaccines has paid an initial option fee to Provalis
and will pay all costs connected with the patents underpinning these vaccine
candidates; and

Chiron Vaccines has the right to enter into an exclusive
licence for, or to acquire, these vaccine candidates, in both cases on
pre-determined terms (which include the quantum of staged milestone payments and
royalty rates for the licence).


Commenting on the agreement, Phil Gould, Chief Executive Officer of Provalis
said 'We announced in 2002 that we would focus all of our resources on our
Medical Diagnostics and Pharmaceuticals businesses, and would seek partners to
continue the development of our vaccine development programmes. We are,
therefore, delighted to have reached this agreement with a major worldwide
player in vaccine development such as Chiron Vaccines. This, together with the
earlier deal with GlaxoSmithKline for Haemophilus Influenzae antigens, delivers
potential long term upside for our investors.'


END


Provalis' Internet Website;
http://www.provalis.com

Further proof that Provalis management is turning the corner. Improved 2nd quarter growth, cash balance good, acquisition strategy in place, and G5 marketing beginning.

Provalis PLC 12 July 2004
For Immediate Release

Trading update for Financial Year 2004

G5 now branded as in2it(TM) and to be unveiled at the Diabetes Educators Meeting in Indianapolis in mid-August

Provalis plc (LSE: PRO; NASDAQ:PVLS), the Medical Diagnostics and
Pharmaceuticals Group, is pleased to announce that its unaudited results for the
financial year ended 30th June 2004 are in line with market expectations with:-

Unaudited Group sales of 12.9m;

Pharmaceutical sales 5 per cent ahead of last year at 11.4m;

Medical Diagnostics sales of Glycosal(R) improving in the second half of
the year, with the business achieving annual sales of 1.5m; and

Net cash of 1.8m at 30th June 2004, with an unused bank facility of
up to 3.0m.

Pharmaceutical Developments

The profitable Pharmaceuticals business continues to pursue a number of
development projects, particularly the acquisition of further products and the
enhancement of margins on its current product range. Preparations are already
underway for the launch of Erdotin(R), its new mucolytic, onto the UK and Ireland markets early in 2005.

in2it(TM) Chosen as the Brand Name for Provalis' G5 Diagnostic Platform

Preparations for the launch of Provalis' in2it(TM) A1c(previously code named
G5), our new 'point of care' diabetes management system, in Autumn 2004 continue
following the filing of the regulatory dossier in the USA in mid-June. Interest
in the product is exceeding our expectations, with our in-house US sales force
already receiving enquiries from a number of health management organisations and
distributors. in2it(TM) A1c is to be formally unveiled at the American Diabetes Educators Meeting in Indianapolis in mid August.

Phil Gould, Chief Executive of Provalis, commented, 'We are pleased that the 2nd
half of the year has seen stronger Group sales. In addition, completion of
in2it(TM) A1c (the brand name for G5), our new diabetes management system, and its filing with the US FDA, were significant developments for the Group. The
projected Autumn launch of in2it(TM) A1c in the US, using our own direct sales
force, is the next important milestone in developing a branded point of care
diagnostics business focused on chronic disease.'


END

Provalis' Internet Website

Nice jump into the blue this morning - but why ?. All buys so far even if the last two have been recorded as unknown

Probably just a reaction to the recent downward price movement. I would hope to see a slow rise all the way to the next set of results on Sept 16th. I should also add that G5 FDA approval should come in early September, with product launch in October.

pachandl - approval has come two weeks early - 28% increase and still buying - a good set of results in 3 weeks should see this little gem back to past glory and beyond.

Oak - back from my hols and nice to see the good news. Good results plus a clear marketing strategy for G5 will see this past the 10p mark within a few weeks.

Oh dear what now - just as I was getting used to being in the blue - It has to-day left me feeling that colour. Why why why???

Provalis PLC
06 September 2004
For Immediate Release 6 September 2004


PROVALIS PLC

NOTIFICATION OF PRELIMINARY RESULTS
for the year ended 30 June 2004

Results Date: Friday 17 September 2004

On behalf of our client, Provalis plc (LSE: PRO; NASDAQ: PVLS), the Medical
Diagnostics and Pharmaceuticals Group, we notify the London Stock Exchange that
the Company will now be announcing its Preliminary Results for the year ended 30
June 2004, on Friday 17 September 2004.

The following meetings will be held on the day of the results, at Buchanan
Communications, 107 Cheapside EC2V:

Analysts : 10.00 am
Press : 11.30 am
Private Client Brokers Lunch : 12:45 pm

Provalis had originally announced that results would be announced on Thursday
16th September. The Company trusts that this one day change will not cause any
inconvenience.

For further information please call:

Lisa Baderoon
Buchanan Communications Tel: 020 7466 5000


This information is provided by RNS
The company news service from the London Stock Exchange

A reasonable tick up today - helped by Pro's performance on the Nasdaq. Also accompanied by better than avergae volume - let's hope that some contract announcement with one of the USA hospitals will follow over the next few weeks in order to maintain current momentum.

A reasonable report, some good news on in2it potential demand, and nice to see that the institutions did not subscribe to the rights issue at a ridiculously low price. Pach.

Provalis FY loss widens as expected; in2it takes off in US UPDATE
AFX

LONDON (AFX) - Provalis PLC said its loss before tax and exceptionals widened in the year to June 30 2004, as expected. The group also highlighted the exceptionally positive response it has received in the US for its new 'point of care' diabetes diagnostic product in2it A1c.

Group sales for the year fell to 12.9 mln stg from 14 mln in 2003 and the board said current sales in both its businesses are in line with expectations.

In the year under review pharmaceutical sales advanced to a record 11.4 mln stg from 10.9 mln but Medical Diagnostics sales, despite a recovery in the second half, fell to 1.5 mln from 3.1 mln.

Provalis also announced a placing to raise 2.6 mln stg today to help satisfy the 'exceptional and unexpectedly high demand' from US customers for in2it A1c.

The placing for cash of 33,066,000 new ordinary shares was predominantly with institutional investors and at a price of 8 pence each.

Commenting on the full year results, chairman Frank Harding said the highlight of the last year has been the completion of the development of in2it. He said the product has been cleared for sale in the US by the FDA and granted CLIA waiver and the company is now readying itself for its launch onto the US market in the autumn.

'We believe in2it A1c will be the best point of care diabetes testing product that is commercially available.'

Chief executive officer Dr Phil Gould added that the next year will be an exciting one for Provalis.

The US launch of in2it will be followed by the Pharmaceuticals business launching Erdotin in the UK and Ireland early in 2005. The company then anticipates applying for US regulatory approvals for the second test for the in2it diagnostic platform in the first half of calendar 2005.



The board said it remains committed to building a viable, fast growing and diversified healthcare group that will achieve profitability at the earliest opportunity. 'We believe that the step change in our diagnostics sales potential in the US, coupled with the sound profitable base of our Pharmaceuticals business, will lead to a revaluation of the company by the market.'

newsdesk@afxnews.com

Seems to be attracting buyers when the price falls below 8p. 10 day and 50day MA's intersected in an upward direction (last week). Reasonable evidence of a double-bottom having formed. If so, 7.85 mid-price might easily become a low-point resistance level. By all means shoot me down in flames when things go horribly wrong this afternoon and the share price plummets. Anyone else following this share?

I am, why did you start a new thread?
I've got a better selection of charts at the top of the other one.

I sold at 9.9p earlier this year but am watching for convincing evidence of profits before I decide whether it is worth buying again.

Schroders increases stake to 10% - as notified today. Obviously someone sees potential, although fund managers are notoriously wrong when choosing small cap stocks (unless they are employed by Artemis)!

DT has a short piece about Provalis in the Money Section - mentions concerns about loss of Falk products but recognises potential for in2it. It concludes that the share is "very risky - but the potential upside could be high". It seems a fair reflection of the current position.
IC has Pro as fairly priced but recognises that the US demand for in2it is positive if it can be sustained.
Overall, the press coverage is mildly encouraging although no-one is going to put their head above the parapet until there is evidence of a sustainable order pipeline in the US.

Interesting 750k trade at the end - seems to be a buy if you look at the real bid/offer spread. I wonder whether any other instituion is buying in - probably wishful thinking!

Hatman's chart analysis on ADV is proving unerringly accurate - we are currently in the third wave (3rd part) of a 5 wave pattern. MA lines all starting to point upwards with interesting dissection of 50 and 200 yesterday. A positive update on in2it orders at the next AGM (scheduled for Nov 4th I believe) would really create a firm foundation for upward momentum for the next two months.

I would expect an RNS soon re some institutional buying. 500k buy at 8.5p and a lot of sells soaked up last week.

Slowly but surely:

LONDON (AFX) - Provalis PLC, the medical diagnostics and pharmaceuticals group, said current trading is ahead of last year and in line with market forecasts.

The company also said first shipments to the US of its fully automated diagnostic test platform in2it Alc is planned for this month and that US demand for the product continues to grow strongly.

In the text of a statement to today's AGM, chairman Frank Harding said: 'With the first shipments of in2it A1c now imminent, further tests being developed for the in2it platform and the planned launch of Erdotin, 2005 promises to be a busy and productive year for Provalis. We anticipate 2005 as being the year which sees significant progress towards Provalis' emergence as a sustainable, growing and profitable healthcare group.'

Provalis said the highest margins on sales of in2it occur in the US and the strong demand from that country means production for this market will take all the company's capacity until summer 2005.

'We do, however, expect to gain European regulatory approval shortly and, as we are already in discussions with a number of pan-European distributors, we will be in a position to launch in2it A1c in Europe as soon as capacity is available,' Harding said.

The chairman said the withdrawal of Merck's Vioxx from the market last month gave Provalis the opportunity to promote its Diclomax product, a medicine for use in the treatment of musculo-skeletal disorders,.

'Although this campaign has only just started, we have seen some early signs of a potential increase in demand for Diclomax,' he said.

He said he hopes the increased sales from the campaign will mitigate some of the negative effects increased generic competition will have on Diclomax.

Finally, Harding said Erdotin, Provalis' new mucolytic product for use in a number of respiratory illnesses, continues to progress through registration and the company remains on schedule to launch the product early in 2005.

newsdesk@afxnews.com

From Supermum on ADVFN:

PRO coming off a support at just below 6p as a double bottom and broken through the shorter term down trend through 8p, I'd look at that as support - at 9.5 its in a resistance area and working its way through, once its through 10.5 - I would say that it may stand a chance... its def not a stock that will go up in a straight line - there will be dips

LONDON (AFX) - Provalis PLC said has now made the final payment to Pfizer Inc for Diclomax, which it acquired in Dec 2001 for 14.5 mln stg .

The price was to be paid via an initial 1.9 mln stg and further instalments over three years.

Provalis chief executive Phil Gould said: 'In the three years since Provalis acquired Diclomax, the product has remained profitable, sales have been maintained above 6 million pounds per year and market share has been increased.

'The annual payments to Pfizer have totalled 4.6 million pounds each year, and with this final payment having been made the cash generated from sales of Diclomax is now available to fund the further development of the group,' he added.

newsdesk@afxnews.com

lam

In the light of the current controversy surrounding Cox-2 inhibitors, I would have thought that Diclomax sales will remain steady for a couple of years. This should contribute 4m+ to the bottom-line, enabling further platform development of in2it. Currently the sp seems stuck in the resistance area but this seems quite positive in the light of the large number of sells last week. Keeping my fingers crossed - not a share for widows and orphans.

The recent price drop suggests that momentum has stalled. Pro is a small company that has to prove itself before any real buying can take place. The MMs obviously want to drum up some turnover or they will get nothing. Without newsflow the only thing that the MMs can do is drop the price. I am hoping for consolidation around the current range but nothing will happen until Pro management makes a positive statement. Hatman's analyis on Adv had proved unerringly accurate but the wave theory has now dissipated and we need to find a solid base again. A shame - I was getting quite excited!

6.9mill sell - are people jumping ship or has a big seller finally left the scene clearing the way for an upward movement?

Finally some positive news to stabilise the share price:

Provalis PLC
03 December 2004


For Immediate Release 3rd December 2004


Provalis plc


Provalis Makes First Shipments of in2it(TM) A1c to the US
in2it(TM) A1c Exhibited at Medica in Dusseldorf to support European launch

Provalis plc (LSE: PRO; NASDAQ: PVLS), the Medical Diagnostics and
Pharmaceuticals Group, is pleased to announce that its Medical Diagnostics
business is today making the first commercial shipment of in2it(TM) A1C to the
US. in2it(TM) A1c, Provalis' new, fully automated, diabetes diagnostic test, is
sold directly to a network of sub-distributors in the US by Provalis Diagnostics
USA, the US based sales organisation established by Provalis earlier this year.

In addition, Provalis exhibited in2it(TM)A1c at Medica, Europe's leading
exhibition of medical diagnostic equipment, last week. Response from attendees
was very positive and discussions are on-going with selected distributors
regarding the product's launch in Europe, which is scheduled for the Summer of
2005.

Phil Gould, Chief Executive Officer of Provalis, said 'I am delighted that
shipment of in2it(TM) to the US market is now underway. We are extremely pleased
by the enthusiastic response to the product in the US, with orders continuing to
build following the exceptionally strong response from many sectors of the US
healthcare market. in2it(TM)'s ease and speed of use, economic pricing and
laboratory-standard performance have been major selling points for us and we
look forward to a steadily increasing stream of weekly shipments over the next
few months and to European launch in Summer 2005.'


END

Provalis' Website;
http://www.provalis.com

Excellent news - also ensures that we are not just a one product company.

Provalis PLC
13 December 2004


For Immediate Release 13th December 2004

Provalis plc

Provalis signs Vaccine Option Agreement with Aventis Pasteur

Provalis plc (LSE: PRO; NASDAQ:PVLS), the Medical Diagnostics and
Pharmaceuticals Group, today announces that it has signed an option agreement
with Aventis Pasteur, the vaccines business of the sanofi-aventis Group, for the
development of vaccine candidates to prevent streptococcus pneumoniae infection.

Under the terms of the agreement, Aventis Pasteur is granted a 24 month
exclusive option to evaluate Provalis' protein based antigen vaccine candidates
to prevent streptococcus pneumoniae infection. Aventis Pasteur will pay an
initial option fee to Provalis and will pay all costs, back dated to May 2004,
connected with the patents relating to these vaccine candidates. Aventis Pasteur
has the right to enter into an exclusive license for these vaccine candidates on
pre-determined terms, which include multi-million dollar milestone payments and
commercial royalty rates on any product commercialised.

Commenting on the agreement, Phil Gould, Chief Executive Officer of Provalis,
said, 'We are delighted to have reached this agreement with a world-wide player
in vaccine development such as Aventis Pasteur. This now represents our third
major agreement within our vaccine portfolio - the others being with
GlaxoSmithKline and Chiron Vaccines - and completes our partnering programme.
This means we are committed to no further spend for the Group, whilst retaining
the potential to generate considerable upside for our shareholders in the
future.'

END

Provalis' Internet Website ;
http://www.provalis.com

A reasonably positive interim trading statement - but it is important that the necessary increase in manufacturing capacity is achieved by August this year.

RNS Number:1177H
Provalis PLC
07 January 2005


For Immediate Release 7th January 2005


Provalis plc

Half Year Trading Update


Pharmaceutical sales advance by 5%

Medical Diagnostics makes first sales of in2it(TM) A1c to the US

Provalis plc (LSE: PRO; NASDAQ:PVLS), the international Medical Diagnostics and
Pharmaceuticals group, is pleased to announce that unaudited sales for the half
year to 31st December 2004 were approximately #6.7 million. This is 5% ahead of
the same period in the previous year (#6.4 million), and is in line with the
Board's expectation.

During the first half of 2005 significant progress was made in both operating
businesses:-


Strong Sales by Pharmaceuticals Business

Sales by the Pharmaceuticals business were some #6.1 million, up 5% on the same
period last year. The second quarter sales were particularly strong, despite the
impact of wholesalers deferring purchases until after the 7% PPRS price
reduction takes effect in January 2005.

Diclomax(R) continues to sell well, helped by the withdrawal of Vioxx from the
market in October 2004 and the continuing uncertainties over other COX2
inhibitors, although the benefit of this has been counter-balanced by an
increase in generic competition. Calceos, our treatment to prevent or treat
osteoporosis, continued to make strong progress in the first half, with sales
significantly advanced over last year.

Medical Diagnostics Business Launches in2it(TM) A1c in the US

Activities within the Medical Diagnostics business were concentrated on
preparing for the US launch of in2it(TM) A1c following receipt of FDA clearance
in August 2004. Since then, the Company has worked with its various
manufacturing partners to bring the product on stream, with the first shipment
of in2it(TM) A1c to the US made in the first week of December.

Sales of the product in the US are being managed directly by Provalis' own sales
team, whose members each have extensive diagnostic experience within the US
diagnostics market. This sales team has established a number of preferred
distributors and key accounts in the US, and has helped achieve early take up of
in2itTM A1c. Indeed, interest in the product continues to grow as we expand our
distribution coverage in the US.

Sales of in2it(TM) A1c will progressively increase through the second half of
the year although, as previously announced, sales will be limited during that
period by our current manufacturing capacity of test cartridges. However,
following the successful fund raising in September 2004, we have begun the
staged implementation of automated manufacture of test cartridges. This remains
on track for completion during the summer of 2005, and should give a several
fold increase in production capacity.

Sales by the Medical Diagnostics business in the first half were some #0.6m,
principally from the supply of Glycosal(R) test cartridges to our existing
distributors. The business remains on course to meet market expectations for
the full year as sales of in2it(TM) A1c increase.

Phil Gould, Chief Executive Officer of Provalis plc, commented: "The first half
year has seen increased sales by our Pharmaceuticals business and a significant
achievement by our Medical Diagnostics business with the approval and launch of
in2itTMA1c in the US. In the second half of the year we will concentrate on
meeting the US demand for in2it(TM) A1c and continuing the development of two
further tests for the in2it(TM) platform, whilst continuing to maximise the
performance of our Pharmaceuticals business."

The Company's interim figures and an overview of trading expectations for the
full year will be presented in March 2005.

END


Provalis' Website; http://www.provalis.com

Is someone building a stake - the sp has not exactly crashed given the constant flow of sells. Probably wishful thinking.

Provalis PLC
25 January 2005


For Immediate Release 25 January 2005


PROVALIS PLC - NOTIFICATION OF INTERIM RESULTS - for the six months ended 31 December 2004


Results Date: Tuesday 1 March 2005 - Web Cast Notification


On behalf of our client, Provalis plc (LSE: PRO; NASDAQ: PVLS), the
International Medical Diagnostics and Pharmaceuticals Group, we notify the
London Stock Exchange that the Company will be announcing its Interim Results
for the six months ended 31 December 2004, on Tuesday 1 March 2005.


The following meetings will be held on the day of the results, at Buchanan
Communications, 107 Cheapside EC2V:

Analysts : 10.00 am
Press : 11.30 am


Running simultaneously to the briefing at 10.05 am will be a live web cast of
the results presentation. To connect to the web cast facility please go to the following internet address approximately 5 minutes (10.00 am) before the start of the briefing: http://mediaserve.buchanan.uk.com.


This presentation will also be available on the Provalis website later that day
at: www.provalis.com


For further information please call:

Lisa Baderoon Buchanan Communications Tel: 020 7466 5000

The market does not seem to have reacted favoyrably to this announcement - although the saving of money will almost certainly avioid any further need for a cash-call (IMHO).

LONDON (AFX) - Provalis PLC said it intends to terminate its listing on NASDAQ.

As soon as possible thereafter, it said it will suspend its registration and reporting obligations to the United States Securities and Exchange Commission (SEC).

Provalis said a review of its secondary listing on NASDAQ concluded that the significant costs and management time necessary to comply with additional requirements introduced by recent changes in United States securities laws far outweighed the benefits of the listing.

This action, which is expected to save the group some 700,000 usd between now and June 30 2006 and at least 400,000 usd in each year thereafter, should not cost more than 50,000 usd.

newsdesk@afxnews.com

Highlights of interims - reasonable progress seems to be the order of the day.

For Immediate Release 1st March 2005


Provalis plc

Interim Results for the six months ended 31 December 2004

Provalis plc (LSE: PRO; NASDAQ: PVLS), the International Medical Diagnostics and
Pharmaceuticals Group, is pleased to announce its interim results for the six
months ended 31 December 2004.

Highlights

Group

Group sales 6.7m (1H2004: 6.4m) with gross profit 3.5m (1H2004: 3.6m)
Group operating loss of 2.7m (1H2004: 1.8m) principally reflecting
additional costs of the US sales operation
Group loss for the period of 1.7m; (1H2004: 2.0m)
Share placing in September raised 2.5m net to support manufacture of
in2it(TM)
Closing cash of 1.1m augmented by the scheduled receipt of 2.0m from
Dr Falk Pharma in January
5.0m three year credit facility arranged with Bank of Scotland in
February 2005
Completion of payments to Pfizer for Diclomax
Option for vaccine license agreement granted to Aventis Pasteur

Medical Diagnostics

US FDA 510K clearance and CLIA waiver of in2it(TM) A1c
US sales management team generating significant demand and orders for
in2it(TM) A1c
First shipment of in2it(TM) A1c to the US made in December 2004
Continuing strong demand for in2it(TM) from US market with shipments steadily
increasing from February
Major interest in in2it(TM) from international markets with European launch
expected by autumn 2005
Project for major increase in cartridge manufacturing capacity for in2it(TM)
on course for completion by July 2005
Further tests for the in2it(TM) platform in development

Pharmaceuticals

Sales of 6.1m (1H2004: 5.8m) with net profitability of 0.8m (1H2004; 1.0m)
Diclomax(R) continued to sell well (2.8m) but market remains turbulent
following Merck withdrawal of Vioxx in October 2004 and increased generic
activity
Sales of Dr Falk products at 2.5m; marketing and distribution of these
products ceased in December 2004 and final compensation payment received by
Provalis in January
Erdotin(TM) continues to progress through regulatory process towards UK and
Irish approvals

Phil Gould, Chief Executive Officer of Provalis plc, commented: 'The first half
of the year saw Provalis achieve most of the key strategic objectives necessary
to provide the platform for significant sales growth in the next financial year.
Most importantly, our US sales team generated strong and continuing demand for
in2it(TM) A1c following the grant of regulatory approvals in August.

Demand for in2it(TM) A1c continues to exceed our manufacturing capacity for test
cartridges. The project to deliver a several fold increase in capacity is well
advanced and should be completed by early in the next financial year. This would
allow sales of in2it(TM) A1c to accelerate markedly and, despite the challenges
facing our Pharmaceuticals business, rapidly move the Group as a whole towards
profitability.'


END

It's about time the directors started reaching into their pockets!

Provalis chief exec, finance director buy shares
AFX


LONDON (AFX) - Provalis PLC said chief executive Phil Gould, finance director Peter Bream and director FA Harding have each acquired 100,000 ordinary shares in the company at 5.75 pence each.

Gould now holds 450,689 shares, representing 0.12 pct. Bream now holds 221,462 shares, representing 0.06 pct, and Harding now holds 366,058 shares, representing 0.1 pct.

newsdesk@afxnews.com

slm/

Inv Chr has Pro as "fairly priced" with loss of Dr Falk products and increased generic competition for Diclomax squeezing profits, but counter-balanced by demand for in2it exceeding supply. Probably a faiur assessment at present until increased capacity comes on stream.

see what happens in 2months

Jaded - I think most of us are waiting for a July update on progress towards increasing manufacturing capacity and current level of damand for in2it in the USA. If the rns is positive then we will start moving up towards the 10p mark quite quickly.

At last some good news to halt the downward trend in the sp. I would hope that we can start recovering lost ground and move back towards an sp in the 7-8 range within the next couple of months:

Provalis PLC
26 July 2005



Provalis plc


Update on progress of in2it(TM) A1c


Provalis plc (LSE: PRO; NASDAQ: PVLS), the international medical diagnostics and
pharmaceuticals group, is today providing an update on the progress of its
flagship product for the diabetes market, in2it(TM) A1c.


Shipments of the enhanced in2it(TM) A1c cartridge have now commenced to the USA,
as envisaged in Provalis' June statement. The upgraded analyzer was already in
production and all existing distributors are being restocked with both the
upgraded analyzer and cartridges. In addition, the next phase of the planned
expansion of the cartridge manufacturing capacity is now available, on schedule,
to meet expected demand through the rest of this year and into 2006. Supplies
will build steadily over the next few months and will utilise this increased
cartridge manufacturing capacity.


Phil Gould, Chief Executive Officer of Provalis said,


'We have rapidly made the small design changes to the cartridge manufacturing
process and have already started to ship the enhanced product to the USA.
Demand remains strong for a cost-effective and easy-to-use glycated haemoglobin
testing product for diabetes, given over 17 million Americans are directly
affected.'



26 July 2005



For further information:-


Provalis plc
Dr Phil Gould, Chief Executive Officer 01244 833463
Peter Bream, Finance Director 01244 833552

College Hill
Adrian Duffield/Corinna Dorward, 020 7457 2815/2803

Further positive newsflow - let's hope they can convert this into sales.

Provalis says in2it diabetes diagnostic product gets NGSP certification
AFX


LONDON (AFX) - Provalis PLC said in2it A1c, its flagship diabetes diagnostic product, has been certified by the National Glycohaemoglobin Standardisation Program (NGSP).

NGSP is an independent quality assessment run by the University of Missouri. Provalis said the importance of the certification is such that the American Diabetes Association only recommends, and many health care providers in the USA will only use, tests that are NGSP certified.

Provalis also said its brand building awareness drive in 2005 has won first place in the recent Bio-medical Marketing Association Awards in the category of Product Brand Creation.



newsdesk@afxnews.com

slm/

This is starting to look interesting although I am assuming that the sudden rise today is suggesting that some other positive news is in the "wind":

UK small cap opening - Provalis continues to rise on NGSP certification
AFX


LONDON (AFX) - Shares in Provalis continued to gain after this week's announcement that its flagship diabetes diagnostic product in2it A1c has been certified by the National Glycohaemoglobin Standardisation Program.

At 8.07 am, the shares were trading at 6.37 pence, up 1.12.

AND

Thu 22:29 Wall Street - European ADRs Provalis soars 184% on product news; Total falls AFX UK Focus
LOS ANGELES (AFX) - Shares of U.K. medical diagnostics and pharmaceutical group Provalis surged nearly 200% on positive news for its diabetes diagnostic product on Thursday among U.S.-shares of European companies.

The Bank of New York Europe American Depositary Receipt Index closed down 0.89 point to 130.19, while the overall Composite Index lost 0.88 point to 126.02.

Earlier, banking stocks weighed on European markets. Germany's DAX 30 index closed down 1%, France's CAC 40 index fell 0.8% and the U.K.'s FTSE 100 index slipped 0.3%.

Provalis jumped $5.51, or 184.3%, to $8.50 after the company said its flagship diabetes diagnostic product, in2it(TM)A1c, has been certified by the National Glycohaemoglobin Standardization Program (NGSP).

NGSP is an independent quality assessment run by the University of Missouri.

pachandl - can you explain to me if you know, why there is a different listing of the shares in the US at $8.50 and why they should have risen so much over there? Cheers.

PRO investors,this company's SP is flying and to-morrow it will start to rocket because it has simply a very good product which in my opinion will sell like cheese cakes.

Rob - Shares in US are traded as ADRs and probably worth about 30 times the value of each UK share. A while back Pro said they would be delisting from US because of the exceptionally expensive accountancy practices. Hope that helps.

Robstuff- for you - copied from adv BB - I am sure rmart will not be unduly upset :


rmart - 8 Aug'05 - 11:35 - 4327 of 4342

Provalis may suspend its SEC registration and reporting obligations if the
number of US residents who hold Provalis securities (either ADRs on NASDAQ or
ordinary shares on the London Stock Exchange), directly or through nominees,
falls below 300.


In order to reduce the number of US residents holding Provalis securities to
less than 300, Provalis intends to implement the following as soon as possible:


* Give written notice of termination of Provalis' ADR
programme, effective in 90 days;

* Upon the termination of the programme at the end of this 90-day
notice period, no further transfers of ADRs will be permitted and
trading of ADRs on NASDAQ will cease; as a consequence, there will be no
liquid trading market for the sale or purchase of Provalis ADRs;

* Holders of any ADRs which remained outstanding would then have
2 months in which to surrender their ADRs in return for Provalis ordinary
shares, subject to payment by the holder of a cancellation fee;

* Any ADR holders that surrender their ADRs in return for
Provalis ordinary shares would subsequently hold and trade the ordinary shares
on the London Stock Exchange; and

* On the expiry of this 2 month period, the ordinary shares underlying any
remaining outstanding ADRs would be sold by the Bank of New York
(the provider of Provalis' ADR programme) on the open market, with the sale
proceeds distributed to the ADR holders in cash.

So - buys outstrip sells 2 to 1 and the price drops!
The brokers are playing a sucker punch = drop the price - shake the tree - watch the suckers fall out - then motor the price up - buy the stock cheap and drive the price up to sell expensive

If you have this stock keep it! Don't let the brokers con you.

Why the drop today - is there any news out there?

hi bharathi raj WELL DONE I THINK YOUR EXACTLY RIGHT,WITH DIABETES GETTING A BIGGER AND BIGGER PROBLEM THE SP SHOULD BE FLYING,THIS IS A GREAT TIME TO BUY BUY BUY,WATCH THIS BY XMAS CAN SEE IT AT 12/15 I AM HOLDING 300K @ 7.4 I AM NOT SELLING.

BHARATHI RAJ TREE SHAKING BY THE MARKET MAKERS,I AM GOING IN AGAIN.

Finally Gould departs the scene. A very good technician but has failed to capitalise on Pro's lead in the diabetes testing market. Good news on the whole I feel.

YEE OF LITTLE FAITH BACK IN @6.25 100K I AGREE WITH PACHANDI THIS WILL BE STRONG WITH PETER WOODFORD ON BOARD

why all sells today - do we have some news out there?

All rather disappointing - how can a company with a world-beating product handle things so badly. I remain invested and still remain confident of long-term growth but apologise to anyone who followed my "advice" and still holds.

UK smallcap opening - Provalis down as FY losses widen
AFX

LONDON (AFX) - Sellers were about in Provalis, 1.00 lower at 3.87 pence, following news that the company's pretax losses widened to 5.6 mln stg from 1.8 mln in the year to end-June on the back of lower sales of 10.4 mln against 12.9 mln.

The medical diagnostics and pharmaceuticals group said the year had been challenging, adding sales by the Medical Diagnostics and Pharmaceutical businesses were lower than anticipated despite good progress made by Medical Diagnostics with operational and strategic developments.

COPYRIGHT

Copyright AFX News Limited 2005. All rights reserved.

So what now? .....opinions anyone..

Totally fed up at present. Next update will be early December I have heard. We really need some clear figures about sales of Intuit and positive news about licensing new products (or sale of the pharma division).

pachandl - I don't think Intuit is going to help this share one little bit, but maybe In2it will help. :-))

Apologies for that slip-up. Obviously my memory has started to work phonetically.

700202 re your post 45 of 10 Aug. Are you refilling your boots today?

I thought I might drop in at this point for a dabble. Could be an interesting couple of months.

Nam

Hi
Can anybody tell this novice trader come investor whether this share is oversold ? Certainly a good time for a dabble with the huge variance in SP going on recently. I bought and sold yesterday and made 216 within 4 hours on only 2000 just by bottom feeding in the morning and out for lunch !
Anyone know why the MM`s are playing silly buggers with this at the moment. I know it didn`t have great results but surely that has already been factored out in the recent SP slide.
Anyone out there who can enlighten me, I`d be mighty obliged. Thanks. Obe

Provalis have delisted from Nasdaq and cancelled their USA ADR programme. MAx 5.5 millshares to come back to uk if they all take cash. In last 4 days buys have been ahead of sells by 3.5 million in total and yet we have not moved up. We will do soon IMO when the sales of the USA shares stops . imo

Anything under 5p for provalis is a steal imo.

I said it would be an interesting time. Jumping on in a smallish way to see how interesting. Sub 1.83p to buy. Any thoughts out there?

Nam

IT COULD GO LOWER LOWER LOWER////IT MAY GO BUST///

It seems there is some bottom-fishing going on at present. Unlikely to be any news before the December update - unless there is an offer for the pharma division.

This isn't the bottom, pach - that was last Friday when one should have jumped on board. In profit, esp. since 3pm today. More to come?

Nam

Oh yes.

Nam

Best of luck Nam - at least someone seems to be making a profit out of holding Provalis shares !

Thanks Pach

Got in at 1.2p, now out. Profit taken. Trebles all round.

Nice when this happens, although opportunity doesn't present itself that often.

Happy hunting.

Nam

sinking fast - what a rip -

Everything is down, but I must admit that I thought that all bad news had been factored into the price (whatever negative issues hit the general market).

is this a turning point??

Has anyone spotted anything in the press regarding the sudden sp rise? Perhaps they have resolved the short shelf-life problem?

I notice on the website that Evolution have made some statement about Pro (presumably) but without any recommendation. Anyone know any different?

2006 ESTIMATES
Broker Date Pretax Eps Dps
m p p
Nomura 15-Jun-05 SELL r (5.20) r (1.00) r - r
Numis Securities Ltd 22-Nov-05 RED + (2.00)
Evolution Securities Ltd 12-Jan-06 +


By the way, 10 MA line is about to cross 50MA line - which has (up till now) always proven very positive for my shares.

Yahoo Finance on Thursday (courtesy of Kim on adv)
London (ShareCast) - Diagnostic group Provalis shot to the top of the Techmark on news of a widening of its strategic review to include all possibilities.

"The board has widened its review to consider all strategic and funding options available to the group and how best to maximise value for shareholders," chairman Frank Harding said.

'In advance of the outcome of this strategic review, the board is in the process of significantly reducing the group's cash expenditure in the short and medium term. It has already cut the US and central cost bases substantially," the statement added.

Finally, some news about future financing of In2it.

Provalis chairman, FD to step down; sells assets of health unit for 10.5 mln stg
AFX


LONDON (AFX) - Provalis PLC said its chairman, Frank Harding, and finance director, Peter Bream, are to step down and will replaced by non-executive director Alan Aikman and director of finance Mark Keen respectively.

The company also said it has agreed to sell assets of its Provalis Healthcare Ltd unit to Kogen Ltd, an affiliate of Northern Ireland's Galen Ltd, for 10.5 mln stg.

The company said the assets include contracts, goodwill and intellectual property rights relating to Provalis Healthcare's products, and the stocks of Provalis Healthcare.

Interim CEO Peter Woodford said the disposal allowed the company to concentrate on its Medical Diagnostics division and 'provides us with a financial platform from which the group can address the technical issues associated with in2it'.

newsdesk@afxnews.com
har
COPYRIGHT

TechMark movers: Provalis rides high on sale
Wed 01 Feb 2006

LONDON (SHARECAST) - Shares in medical diagnostics group Provalis moved ahead, topping the techMark stocks after it sold its pharmaceutical division to Provalis Healthcare for around 10.5m.

The group will receive 9.5m plus around 1m for the stock of the products, payable in cash on completion, before transaction costs of about 0.5m.

Provalis said net cash proceeds of some 10m would be used primarily to repay the entire borrowings of Provalis, which are currently around 5.2m.

Telecoms carrier Thus was the major faller in the index after agreeing to buy United Utilities' telecoms arm, Your Communications, in an all-share deal.

United Utilities will receive 391m new shares in Thus, worth 58.8m. It means the utilities firm will hold approximately 22.5% in Thus once the deal is finalised.

Thus also announced that it reached agreement on the terms of a recommended cash offer for Legend Communications at 40p per share in cash valuing the business at about 11.5m.

FTSE TechMARK - Risers

Provalis (PRO) 2.38p +13.10%
Gresham Computing (GHT) 107.00p +10.88%
Aveva Group (AVV) 1,115.50p +7.36%
Filtronic (FTC) 164.00p +4.46%
Elan (ELA) 12.93 +4.27%
Medisys (MDY) 2.05p +3.80%
Dicom Group (DCM) 231.00p +3.36%
SurfControl (SRF) 585.00p +3.04%
Royalblue (RYB) 812.00p +2.98%
Axon (AXO) 317.00p +2.18%

FTSE TechMARK - Fallers

Thus Group (THUS) 14.25p -5.00%
XTL Biopharmaceuticals (XTL) 37.25p -3.87%
TTP Communications (TTC) 23.50p -3.09%
Phoenix IT Group (PNX) 325.00p -2.99%
Axis-Shield (ASD) 277.00p -2.72%
Microgen (MCGN) 74.50p -2.61%
Indigo Vision (IND) 375.00p -2.60%
GB Group (GBG) 33.00p -2.22%
Ferraris Group (FER) 90.00p -2.17%
Kingston Communications (KCOM) 67.50p -2.17%

They certainly are putting all their eggs in one basket - keeping my fingers crossed because In2it has always been the reason that I invested in Pro in the first place:

AFX
LONDON (AFX) - Provalis PLC said it is in discussions with a number of parties, which may lead to the sale of the business or the assets of its Medical Diagnostics division.

These discussions are at an early stage, it added.

The company said today's EGM approved the sale of assets of its Provalis Healthcare Ltd unit.

After the disposal, Provalis will have cash balances of

approximately 3.8 mln stg.

This cash will allow Provalis to continue resolving 'technical issues associated with in2it', and to fully pursue all available options for the Medical Diagnostic division.

newsdesk@afxnews.com
jfr
COPYRIGHT

Well I hold my hands up and admit that I called this one wrong - alth9ough see some interesting thoughts from ADV at the end.

Provalis H1 losses widen as co considers sale of Medical Diagnostics ops UPDATE
AFX
LONDON (AFX) - Provalis PLC reported widening losses for the six months to Dec 31 2005 as it said talks continue with a number of interested parties regarding the possible sale of its medical diagnostics division.

This would lead to an eventual winding up of the business after a distribution of any remaining cash, the group said.

Provalis, which has been carrying out a strategic review of its operations, also said today that Peter Woodford will be continuing as interim chief executive until the end of June at least.

Provalis sold part of its Pharmaceuticals business in February, managing to raise enough to repay its borrowings and leaving the group debt free. The resulting cash balance, of around 4 mln stg is being used to continue the resolution of technical issues associated with in2it.

The in2it analyser is the flagship product of the Medical Diagnostics business. This product carries out diagnostic tests at the point-of-care using a disposable test cartridge. Sales of in2it, whilst still continuing at a very low level, will continue to be disappointing until certain technical issues are resolved, which will take a number of months, the group said.

The group said it now believes that it is not in a position to fully exploit in2it's potential in the absence of further equity funding or borrowing facilities.

It is therefore considering a number of options for the Medical Diagnostics division including the possible sale of the business or assets, or a joint venture, licensing or partnering agreement with a third party.

If sold, Provalis said it intends to distribute the cash remaining within the group to shareholders as part of a solvent winding-up.

Provalis' first half results showed a pretax loss from continuing opeations of 3.7 mln stg, compared with a pretax loss of 3.5 mln a year earlier.

Total group revenues for the six months were 2.6 mln stg, down from 6.7 mln.

Sales in the Medical Diagnostics business were 0.4 mln stg, down from 0.6 mln in the prior year. These sales were predominantly of Glycosal, the group's first generation diagnostic test, for which demand appears to be steady.

The loss for the business over the period was 2.6 mln stg, a slight increase from a 2.4 mln loss in 2004 after increased manufacturing overheads in anticipation of the expected growth of in2it.

Sales in the Pharmaceuticals business were 2.2 mln stg, down from 6.1 mln after the group stopped distributing Dr Falk Pharma products and also due to lower sales of Diclomax following the introduction of a generic competitor in October 2004.

The loss for the period for this business was 1.1 mln stg compared to a profit of 1.5 mln.

ADV - courtesy of Mudbath:

1. ALL IS NOT LOST. Far from it. Do you remember the partnership agreements ,announced in 2004,regarding the development of the Provalis vaccine portfolio,with Glaxo,Chiron and Aventis Pasteur? These have the potential to provide"considerable upside for our shareholders"[PROVALIS] PLUS,"multi million dollar milestone payments AND c ommercial royalties on ANY product commercialised"[PROVALIS].This potential still remains .The directors do make brief reference to the vaccine partnerships in todays interim announcement,conveniently overwhelmed however by the deluge of BEARISH SPIN. THIS LOOKS TO ME LIKE A CLASSIC SHAKEOUT.WATCH OUT for a large buyer mopping up the stock being virtually GIVEN AWAY and watch out for A BUYOUT proposal seeking to do a favour to shareholders with an offer of circa 2 pence.THESE SHARES are on the way up.

VACCINES.The actual statement today from provalis stated"IT(Provalis)does have potential income from milestone payments and royalties".Spot the difference in tone ....Shares have already regained 33% from the days early morning low. DO NOT bail out now.(Just my view.I am a shareholder and have done very well with PRO having ditched a big holding at 14 pence before now rebuying).